BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12570697)

  • 1. Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
    Monaco EA; Vallano ML
    Curr Med Chem; 2003 Mar; 10(5):367-79. PubMed ID: 12570697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction.
    Weishaupt JH; Kussmaul L; Grötsch P; Heckel A; Rohde G; Romig H; Bähr M; Gillardon F
    Mol Cell Neurosci; 2003 Oct; 24(2):489-502. PubMed ID: 14572469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibitors of cyclin-dependent kinases.
    Knockaert M; Greengard P; Meijer L
    Trends Pharmacol Sci; 2002 Sep; 23(9):417-25. PubMed ID: 12237154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitors: novel anticancer agents.
    Mani S; Wang C; Wu K; Francis R; Pestell R
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
    Fischer PM; Lane DP
    Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological relevance of CDK inhibitors in Alzheimer's disease.
    Malhotra N; Gupta R; Kumar P
    Neurochem Int; 2021 Sep; 148():105115. PubMed ID: 34182065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
    Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexities in the development of cyclin-dependent kinase inhibitor drugs.
    Sausville EA
    Trends Mol Med; 2002; 8(4 Suppl):S32-7. PubMed ID: 11927285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
    Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
    J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 5 (CDK5) and neuronal cell death.
    Weishaupt JH; Neusch C; Bähr M
    Cell Tissue Res; 2003 Apr; 312(1):1-8. PubMed ID: 12684868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.